S-adenosylmethionine is a key intermediary in transmethylation reactions, polyamine synthesis and the formation of cysteine and taurine.' Factors that greatly affect its metabolism may therefore have serious consequences.
L-3,4-dihydroxyphenylalanine (levodopa)
is used in humans in the treatment of Parkinsonism and dystonias,2 and also in some inborn errors of metabolism where it bypasses the metabolic block. 3 The normal route of metabolism of levodopa is decarboxylation to form dopamine,4 however, when given in pharmacological doses it is methylated by catechol-0-methyltransferase to form 3-methoxytyrosine in a reaction that uses S-adenosylmethionine as a methyl-donor.5 In 1970, Wurtman et al showed that administration of a single dose of levodopa to healthy rats (in an amount equivalent to that used to treat Parkinsonism in humans) caused a marked fall in brain S-adenosylmethionine concentrations for up to six hours. 6 It has also been shown that in rodents levodopa reduces the methylation of noradrenaline,7 and that this can be reversed by the administration of S-adenosylmethionine. ' In this paper we demonstrate that elevation of levodopa concentrations in the central nervous system in children causes a marked reduction in the concentration of S-adenosylmethionine in the cerebrospinal fluid (CSF), and that this is accompanied by raised levels of 3-methoxytyrosine.
Patients and methods Lumbar CSF was collected from three children with inborn errors of pteridine metabolism (two with dihydropteridine reductase deficiency and one with a tetrahydrobiopterin synthesis defect) and one child with akinetic mutism before and after initiation of therapy with levodopa. In addition, CSF was collected from two children with aromatic-L-aminoacid decarboxylase (L-AADC) deficiency before and after therapy with pyridoxine. Patient details are given in table 1. The patients with L-AADC deficiency will be the subject of a separte report; however, they showed marked accumulation of levodopa and 3-methoxytyrosine in the CSF which was partially responsive to treatment with pyridoxine. The third millilitre of CSF was frozen at the bedside on solid carbon dioxide and stored at -70'C until analysis. CSF S-adenosylmethionine was measured by high performance liquid chromatography (HPLC) with electrochemical detection.9 CSF levodopa and 3-methoxytyrosine were measured by HPLC with fluorescence detection; the stationary phase was a 25 x 0-4 cm Apex 5 gm ODS column maintained at 35°C, the mobile phase 0 05 M sodium acetate buffer pH 4 75 containing 48 pM EDTA and 500 p1/1 ndibutylamine. Flow rate was 1-3 ml/min, and detection was by a Perkin-Elmer LS-3 fluorescence detector with the excitation wavelength and emission wavelengths set at 278 nm and 320 nm respectively. CSF 5- Reference ranges for the CSF metabolites were obtained by analysis of CSF taken from children with a wide variety of metabolic or neurological disease in whom disturbance of these pathways was not expected.
For statistical analysis all patients were treated as a single group. The patients investigated before starting levodopa were grouped with those with L-AADC deficiency receiving treatment with pyridoxine; and, vice versa, those taking levodopa were grouped with L-AADC deficient patients before treatment. Statistical analysis of the data pairs used the paired t-statistic and that of linear trends used analysis of variations. Mean differences are expressed as means (95th centile confidence limits).
Results
In all patients receiving levodopa there was a marked fall in CSF S-adenosylmethionine concentration and a rise in 3-methoxytyrosine concentration (table 2) . Likewise, treatment of the patients with L-AADC deficiency with pyridoxine led to a fall in CSF levodopa and 3-methoxytyrosine concentrations that was associated with a rise in CSF S-adenosylmethionine. When all the results were considered together the mean fall in S-adenosyl-methionine concentrations was 96 (41-151) nM (p = 0 007), and the mean rise in 3-methoxy- pyridoxine to the patients with L-AADC deficiency (leading to a fall in CSF levodopa concentrations) produced a rise in CSF Sadenosylmethionine. This suggests that in p = 0 02). these patients the endogenously formed stration of levodopa was also causing a decrease in Siously high adenosylmethionine concentrations in the cend the CSF tral nervous system. ons to fall
The main pathway for the metabolism of exogenously administered levodopa involves tient 3, on methylation to 3-methoxytyrosine using Sregression adenosyl-methionine as the methyl-group tn 3-meth-donor.5 This was confirmed in our patients g 1).
where administration of levodopa (or the howed no presence of endogenous levodopa in the levodopa patients with L-AADC deficiency) led to the -2-5 MM formation of 3-methoxytyrosine. (fig 3) . Similar findings have been observed in rodents,'5 in which the ability of the brain to buffer the increased demand for methyl groups caused by levodopa administration is via a folate dependent pathway.'3 16 S-adenosylmethionine plays a key role in many metabolic pathways. These include methyltransfer reactions, aminopropylation reactions to form the polyamines and as a precursor for the transulphuration pathway' (fig 3) . Evidence that decreased turnover of Sadenosylmethionine may be important in the pathogenesis of human neurological disease is suggested by the pharmacological effect of Sadenosylmethionine in depression'7 and our recently reported findings that it may be the cause of the demylination seen in inborn errors of folate metabolism.'2 The linear relationship between central S-adenosylmethionine and 3-methoxytyrosine concentrations indicates that the higher the dose of levodopa given, the greater the risk of depressing central S-adenosylmethionine concentrations, and that the dose of levodopa should be the lowest that gives the desired clinical effect.
The present results suggest that it is important to consider administration of S-adenosylmethionine, or other methyl-donors such as methionine and betaine, as an adjunct to levodopa therapy. Both betaine and methionine have been shown to be effective in in-born errors of cobalamin and folate metabolism where decreased concentrations of central nervous system S-adenosylmethionine are to be expected,'2 18 and, in animals, methionine supplementation can prevent the fall in brain S-adenosylmethionine concentrations induced by levodopa. '9 
